Pfizer announced today that PF-06410293, its proposed biosimilar to Humira® (adalimumab), has demonstrated equivalent efficacy to Humira® in a clinical study.  The clinical study gathered data from a 12 week trial in which patients with rheumatoid arthritis were randomized to receive either Humira® or the proposed biosimilar, both in combination with methotrexate. According to the press release, Pfizer now has positive data for three proposed biosimilars, five other biosimilar products in mid-to late-stage development, and several other biosimlar products in early stage development.